Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand

被引:193
作者
Turnidge, John D. [1 ]
Kotsanas, Despina [2 ]
Munckhof, Wendy [3 ,4 ,5 ]
Roberts, Sally [6 ,7 ]
Bennett, Catherine M. [8 ]
Nimmo, Graeme R. [9 ]
Coombs, Geoffrey W. [10 ]
Murray, Ronan J. [10 ]
Howden, Benjamin [11 ]
Johnson, Paul D. R. [11 ]
Dowling, Kate [1 ]
机构
[1] Womens & Childrens Hosp, Adelaide, SA, Australia
[2] Monash Med Ctr, Melbourne, Vic, Australia
[3] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
[4] Ipswich Hosp, Ipswich, Qld, Australia
[5] Univ Queensland, Brisbane, Qld, Australia
[6] Auckland City Hosp, Auckland, New Zealand
[7] Starship Childrens Hosp, Auckland, New Zealand
[8] Univ Melbourne, Melbourne Sch Populat Hlth, Melbourne, Vic, Australia
[9] Royal Brisbane & Womens Hosp, Pathol Queensland, Brisbane, Qld, Australia
[10] Royal Perth Hosp, PathWest Lab Med, Perth, WA, Australia
[11] Austin Hlth, Melbourne, Vic, Australia
关键词
EPIDEMIOLOGY;
D O I
10.5694/j.1326-5377.2009.tb02841.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To document the types of, and mortality from, Staphylococcus aureus bacteraemia in Australia and New Zealand, and determine factors associated with mortality. Design and setting: Prospective observational study in 27 independent or hospital pathology laboratories in Australia (24) and New Zealand (3), employing a web-based database to prospectively record demographic features, selected risk factors, principal antibiotic treatment and mortality data on all patients with positive blood cultures for S. aureus from June 2007 to May 2008. Main outcome measure: 30-day all-cause mortality. Results: 1994 episodes of S. aureus bacteraemia were identified, and complete 30-day follow-up data were available for 1865. Most episodes had their onset in the community (60.8%; 95% CI, 58.7%-63.0%). Methicillin-resistant S. aureus (MRSA) caused 450 episodes (24.1%; 95% CI, 22.2%-25.9%), and 123 of these (27.3%) had a susceptibility profile consistent with community-associated MRSA. All-cause mortality at 30 days was 20.6% (95% CI, 18.8%-22.5%). On univariate analysis, increased mortality was significantly associated with older age, European ethnicity, MRSA infection, infections not originating from a medical device, sepsis syndrome, pneumonia/empyema, and treatment with a glycopeptide or other non-p-lactam antibiotic. On multivariable analysis, independent predictors of mortality were age, sepsis syndrome, pneumonia/empyema, device-associated infection with a secondary focus, left-sided endocarditis, and treatment with a glycopeptide such as vancomycin, but not MRSA infection. Conclusions: S. aureus bacteraemia is a common infection in both the community and hospitals in Australia and New Zealand, and is associated with appreciable mortality. Invasive MRSA infection may be more life-threatening, partly because of the inferior efficacy of the standard treatment, vancomycin. National web-based surveillance of S. aureus bacteraemia and its outcomes is not only important but also easily achievable.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 14 条
[1]  
*AUSTR MEN SURV PR, 2008, COMMUN DIS INTELL, V29, P149
[2]  
*AUSTR SOC ANT, 2007, AUSTR NZ COOP OUTC S
[3]   Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000 [J].
Benfield, T. ;
Espersen, F. ;
Frimodt-Moller, N. ;
Jensen, A. G. ;
Larsen, A. R. ;
Pallesen, L. V. ;
Skov, R. ;
Westh, H. ;
Skinhoj, P. .
CLINICAL MICROBIOLOGY AND INFECTION, 2007, 13 (03) :257-263
[4]   Staphylococcus aureus bacteremia, Australia [J].
Collignon, P ;
Nimmo, GR ;
Gottlieb, T ;
Gosbell, LB .
EMERGING INFECTIOUS DISEASES, 2005, 11 (04) :554-561
[5]   Management of methicillin-resistant Staphylococcus aureus bacteremia [J].
Cosgrove, Sara E. ;
Fowler, Vance G., Jr. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 :S386-S393
[6]   Changing epidemiology of pediatric Staphylococcus aureus Bacteremia in Denmark from 1971 through 2000 [J].
Frederiksen, Marianne Sjolin ;
Espersen, Frank ;
Frimodt-Moller, Niels ;
Jensen, Allan Garlik ;
Larsen, Anders Rhod ;
Pallesen, Lars Villiam ;
Skov, Robert ;
Westh, Henrik ;
Skinhoj, Peter ;
Benfield, Thomas .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (05) :398-405
[7]   Prospective study of 424 cases of Staphylococcus aureus bacteraemia:: determination of factors affecting incidence and mortality [J].
Hill, PC ;
Birch, M ;
Chambers, S ;
Drinkovic, D ;
Ellis-Pegler, RB ;
Everts, R ;
Murdoch, D ;
Pottumarthy, S ;
Roberts, SA ;
Swager, C ;
Taylor, SL ;
Thomas, MG ;
Wong, CG ;
Morris, AJ .
INTERNAL MEDICINE JOURNAL, 2001, 31 (02) :97-103
[8]   Surveillance and epidemiology of MRSA bacteraemia in the UK [J].
Johnson, AP ;
Pearson, A ;
Duckworth, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (03) :455-462
[9]   Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia [J].
Kim, Sung-Han ;
Kim, Kye-Hyung ;
Kim, Hong-Bin ;
Kim, Nam-Joong ;
Kim, Eui-Chong ;
Oh, Myoung-Don ;
Choe, Kang-Won .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) :192-197
[10]   Role of comorbidity in mortality related to Staphylococcus aureus bacteremia:: A prospective study using the Charlson weighted index of comorbidity [J].
Lesens, O ;
Methlin, C ;
Hansmann, Y ;
Remy, V ;
Martinot, M ;
Bergin, C ;
Meyer, P ;
Christmann, D .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2003, 24 (12) :890-896